{"protocolSection": {"identificationModule": {"nctId": "NCT02024971", "orgStudyIdInfo": {"id": "073-011"}, "secondaryIdInfos": [{"id": "JapicCTI-132368", "type": "REGISTRY", "domain": "JapicCTI"}, {"id": "JapicCTI-R150782", "type": "REGISTRY", "domain": "JapicCTI"}], "organization": {"fullName": "Takeda", "class": "INDUSTRY"}, "briefTitle": "Special Drug Use Surveillance of Pioglitazone/Metformin Hydrochloride Combination Tablets Survey on Long-term Use for Type 2 Diabetes Mellitus", "officialTitle": "Metact\u00ae Combination Tablets Special Drug Use Surveillance Survey on Long-term Use for Type 2 Diabetes Mellitus"}, "statusModule": {"statusVerifiedDate": "2016-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-07"}, "primaryCompletionDateStruct": {"date": "2013-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-12-29", "studyFirstSubmitQcDate": "2013-12-29", "studyFirstPostDateStruct": {"date": "2013-12-31", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-09-29", "resultsFirstSubmitQcDate": "2016-09-29", "resultsFirstPostDateStruct": {"date": "2016-11-22", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-09-29", "lastUpdatePostDateStruct": {"date": "2016-11-22", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Takeda", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to investigate the safety and efficacy of long-term use of pioglitazone/metformin hydrochloride combination tablets in the routine clinical setting in patients with type 2 diabetes mellitus for whom therapy with pioglitazone hydrochloride combined with metformin hydrochloride is considered suitable.", "detailedDescription": "This is a special drug use surveillance (survey on long-term use) designed to investigate the safety and efficacy of long-term use of pioglitazone/metformin hydrochloride combination tablets (Metact Combination Tablets) in patients with type 2 diabetes mellitus in the routine clinical setting.\n\nThe following items will also be studied:\n\n1. The effects on safety and efficacy caused by changing the administration method of metformin hydrochloride associated with switching to Metact Combination Tablets\n2. The effects on compliance associated with switching to Metact Combination Tablets\n3. Safety and efficacy in patients who showed inadequate response to pioglitazone hydrochloride and were then switched to Metact Combination Tablets\n\nThe planned sample size was 1000 participants. The usual adult dosage is one tablet of Metact administered orally once daily after breakfast (15 mg/500 mg or 30 mg/500 mg of pioglitazone/metformin hydrochloride).\n\n\\<Precautions Related to Dosage and Administration\\> Edema due to pioglitazone administration has been reported with comparative frequency in women. Therefore, it is preferable to be vigilant for edema and start Metact Combination Tablets at a dosage equivalent to 15 mg of pioglitazone once daily when administering the study drug to women."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Drug therapy"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 1103, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Pioglitazone/Metformin Hydrochloride", "description": "Pioglitazone/metformin hydrochloride combination tablets, orally, for 12 months as prescribed by the standard of care.", "interventionNames": ["Drug: Pioglitazone/metformin hydrochloride"]}], "interventions": [{"type": "DRUG", "name": "Pioglitazone/metformin hydrochloride", "description": "Pioglitazone/metformin hydrochloride combination tablets", "armGroupLabels": ["Pioglitazone/Metformin Hydrochloride"], "otherNames": ["Metact Combination Tablets"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Adverse Drug Reactions", "description": "Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug. Among these, events which are considered possibly associated with a medicinal product are defined as adverse drug reactions.", "timeFrame": "12 months"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Glycosylated Hemoglobin (HbA1c)", "description": "Tabulation of the HbA1c test value and change at each test time point (test value at each test time point after baseline - test value at baseline). A negative change from Baseline indicates improvement. n=number of participants analyzed at each time point. Final assessment is defined as a cumulative assessment of Month 12 and Early Termination Visit data.", "timeFrame": "Baseline and Months 3, 6, 9, 12 and final assessment"}, {"measure": "Change From Baseline in Fasting Blood Glucose", "description": "Tabulation of fasting blood glucose test values and change at each test time point (test value at each test time point after baseline - test value at baseline). A negative change from Baseline indicates improvement. n=number of participants analyzed at each time point. Final assessment is defined as a cumulative assessment of Month 12 and Early Termination Visit data.", "timeFrame": "Baseline and Months 3, 6, 9, 12 and final assessment"}, {"measure": "Change From Baseline in Fasting Insulin", "description": "Tabulation of fasting insulin test values and change at each test time point (test value at each test time point after baseline - test value at baseline). A negative change from Baseline indicates improvement. n=number of participants analyzed at each time point. Final assessment is defined as a cumulative assessment of Month 12 and Early Termination Visit data.", "timeFrame": "Baseline and Months 3, 6, 9, 12 and final assessment"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n-Patients with type 2 diabetes mellitus for whom a physician has concluded that therapy with pioglitazone hydrochloride combined with metformin hydrochloride is suitable and for whom long-term treatment with Metact Combination Tablets is considered necessary.\n\nExclusion Criteria:\n\n-Patients for whom pioglitazone hydrochloride and metformin hydrochloride are contraindicated.\n\n1. Patients with cardiac insufficiency or a history of cardiac insufficiency\n2. Patients with the following conditions (i) Patients with a history of lactic acidosis (ii) Dialysis patients (including peritoneal dialysis) (iii) Patients with cardiovascular conditions such as shock, cardiac insufficiency, myocardial infarction, and pulmonary embolism; patients with severely impaired pulmonary function; and patients with other conditions fostering susceptibility to hypoxemia (iv) Patients with excessive alcohol consumption (v) Patients with dehydration (vi) Patients with gastrointestinal disorders such as diarrhea and vomiting (vii) Elderly patients\n3. Patients with renal impairment (including mild renal impairment)\n4. Patients with hepatic impairment\n5. Patients with severe ketosis, diabetic coma or pre-coma, or type I diabetes mellitus\n6. Patients with severe infection, severe trauma, or pre- and post-operative patients\n7. Patients who are malnourished, starved, debilitated, or have pituitary gland insufficiency or adrenal gland insufficiency\n8. Patients with a history of hypersensitivity to the ingredients in Metact Combination Tablets or biguanides\n9. Pregnant or potentially pregnant women", "healthyVolunteers": false, "sex": "ALL", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "Type 2 diabetes mellitus", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Postmarketing Group Manager", "affiliation": "Takeda", "role": "STUDY_CHAIR"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients with type 2 diabetes mellitus for whom a physician has concluded that therapy with pioglitazone hydrochloride combined with metformin hydrochloride is suitable and for whom long-term treatment with Metact Combination Tablets is considered necessary.", "recruitmentDetails": "Participants took part in the study at 196 investigative sites in Japan from July 2010 to November 2013 (N=1103).", "groups": [{"id": "FG000", "title": "Pioglitazone/Metformin Hydrochloride", "description": "Pioglitazone/metformin hydrochloride combination tablets, orally, for 12 months as prescribed by the standard of care."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1103"}]}, {"type": "Safety Analysis Set", "achievements": [{"groupId": "FG000", "comment": "All participants with available data who were enrolled prior to Day 15 of the start of treatment.", "numSubjects": "1067"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Including 162 patients with missing efficacy data at two or more time points.", "numSubjects": "1067"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}]}], "dropWithdraws": [{"type": "Data Not Available", "reasons": [{"groupId": "FG000", "numSubjects": "30"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "6"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety analysis set", "groups": [{"id": "BG000", "title": "Pioglitazone/Metformin Hydrochloride", "description": "Pioglitazone/metformin hydrochloride combination tablets, orally, for 12 months as prescribed by the standard of care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1067"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "63.7", "spread": "12.01"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "<65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "534"}]}]}, {"title": "\u226565 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "533"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "<20 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}, {"title": "\u226520 to <30 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}]}]}, {"title": "\u226530 to <40 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "33"}]}]}, {"title": "\u226540 to <50 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "91"}]}]}, {"title": "\u226550 to <60 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "218"}]}]}, {"title": "\u226560 to <70 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "347"}]}]}, {"title": "\u226570 to <80 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "294"}]}]}, {"title": "\u226580 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "77"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "450"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "617"}]}]}]}, {"title": "Pregnancy status (Females)", "description": "Female participants only (n=450)", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Not pregnant", "categories": [{"measurements": [{"groupId": "BG000", "value": "450"}]}]}, {"title": "Pregnant", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "69.0", "spread": "15.36"}]}]}]}, {"title": "Weight, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "<40 kg", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}]}]}, {"title": "\u226540 to <50 kg", "categories": [{"measurements": [{"groupId": "BG000", "value": "48"}]}]}, {"title": "\u226550 to <60 kg", "categories": [{"measurements": [{"groupId": "BG000", "value": "138"}]}]}, {"title": "\u226560 to <70 kg", "categories": [{"measurements": [{"groupId": "BG000", "value": "193"}]}]}, {"title": "\u226570 kg", "categories": [{"measurements": [{"groupId": "BG000", "value": "310"}]}]}, {"title": "Unmeasured", "categories": [{"measurements": [{"groupId": "BG000", "value": "371"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "26.61", "spread": "4.738"}]}]}]}, {"title": "Body Mass Index, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "<18.5 kg/m^2", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}]}]}, {"title": "\u226518.5 to <25 kg/m^2", "categories": [{"measurements": [{"groupId": "BG000", "value": "261"}]}]}, {"title": "\u226525 to <30 kg/m^2", "categories": [{"measurements": [{"groupId": "BG000", "value": "280"}]}]}, {"title": "\u226530 kg/m^2", "categories": [{"measurements": [{"groupId": "BG000", "value": "125"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "391"}]}]}]}, {"title": "Duration of Type 2 Diabetes", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.5", "spread": "6.59"}]}]}]}, {"title": "Duration of Type 2 Diabetes, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "<2 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "163"}]}]}, {"title": "\u22652 to <5 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "168"}]}]}, {"title": "\u22655 to <10 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "183"}]}]}, {"title": "\u226510 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "216"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "337"}]}]}]}, {"title": "Healthcare Category", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Outpatient", "categories": [{"measurements": [{"groupId": "BG000", "value": "1049"}]}]}, {"title": "Inpatient", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}]}]}, {"title": "Outpatient and Inpatient", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}]}]}]}, {"title": "History of Allergies", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "No", "categories": [{"measurements": [{"groupId": "BG000", "value": "931"}]}]}, {"title": "Yes", "categories": [{"measurements": [{"groupId": "BG000", "value": "95"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "41"}]}]}]}, {"title": "Presence of Complications", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "No", "categories": [{"measurements": [{"groupId": "BG000", "value": "132"}]}]}, {"title": "Yes", "categories": [{"measurements": [{"groupId": "BG000", "value": "935"}]}]}]}, {"title": "Breakdown of Complications", "description": "Participants may be counted in more than 1 category. DM=diabetes mellitus.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Diabetic complications", "categories": [{"measurements": [{"groupId": "BG000", "value": "169"}]}]}, {"title": "Lifestyle-related diseases (excluding DM)", "categories": [{"measurements": [{"groupId": "BG000", "value": "858"}]}]}, {"title": "Liver diseases", "categories": [{"measurements": [{"groupId": "BG000", "value": "139"}]}]}, {"title": "Renal diseases", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}]}]}, {"title": "Heart or cerebrovascular diseases", "categories": [{"measurements": [{"groupId": "BG000", "value": "144"}]}]}, {"title": "Allergic conditions", "categories": [{"measurements": [{"groupId": "BG000", "value": "84"}]}]}, {"title": "Malignant tumors", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "349"}]}]}]}, {"title": "Complications: Breakdown of Diabetic Complications", "description": "Only participants with diabetic complications are reported. Participants may also be counted in more than 1 category.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Diabetic nephropathy", "categories": [{"measurements": [{"groupId": "BG000", "value": "81"}]}]}, {"title": "Diabetic retinopathy", "categories": [{"measurements": [{"groupId": "BG000", "value": "56"}]}]}, {"title": "Diabetic neuropathy", "categories": [{"measurements": [{"groupId": "BG000", "value": "74"}]}]}]}, {"title": "Complications: Breakdown of Lifestyle-Related Diseases (Excluding Diabetes Mellitus)", "description": "Participants may be counted in more than 1 category.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Hypertension", "categories": [{"measurements": [{"groupId": "BG000", "value": "656"}]}]}, {"title": "Dyslipidaemia", "categories": [{"measurements": [{"groupId": "BG000", "value": "634"}]}]}, {"title": "Hyperuricaemia", "categories": [{"measurements": [{"groupId": "BG000", "value": "79"}]}]}]}, {"title": "Complications: Breakdown of Liver Diseases", "description": "Only participants with liver diseases are reported. Participants may also be counted in more than 1 category.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Hepatic steatosis", "categories": [{"measurements": [{"groupId": "BG000", "value": "107"}]}]}, {"title": "Hepatitis alcoholic", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}]}]}, {"title": "Chronic hepatitis", "categories": [{"measurements": [{"groupId": "BG000", "value": "17"}]}]}, {"title": "Hepatic cirrhosis", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Complications: Breakdown of Renal Diseases", "description": "Only participants with renal diseases are reported. Participants may also be counted in more than 1 category.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Nephrotic syndrome", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}, {"title": "Renal failure chronic", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}]}]}]}, {"title": "Complications: Breakdown of Heart or Cerebrovascular Diseases", "description": "Only participants with heart or cerebrovascular diseases are reported. Participants may also be counted in more than 1 category.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Cardiac failure", "categories": [{"measurements": [{"groupId": "BG000", "value": "17"}]}]}, {"title": "Myocardial infarction", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}]}]}, {"title": "Angina pectoris", "categories": [{"measurements": [{"groupId": "BG000", "value": "55"}]}]}, {"title": "Cerebral infarction (including late effects)", "categories": [{"measurements": [{"groupId": "BG000", "value": "52"}]}]}]}, {"title": "Stages of Cardiac Failure (New York Heart Association [NYHA] Classification)", "description": "Only participants with cardiac failure are reported. NYHA Class definitions are as follows: Class I - No limitation of physical activity; Class II - Slight limitation of physical activity; Class III - Marked limitation of physical activity; Class IV - Unable to carry on any physical activity without discomfort.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Class I", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}]}]}, {"title": "Class II", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}]}]}, {"title": "Class III", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}, {"title": "Class IV", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Complications: Breakdown of Allergic Conditions", "description": "Only participants with allergic conditions are reported. Participants may also be counted in more than 1 category.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Asthma bronchial", "categories": [{"measurements": [{"groupId": "BG000", "value": "33"}]}]}, {"title": "Pollinosis", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}]}]}, {"title": "Rhinitis allergic", "categories": [{"measurements": [{"groupId": "BG000", "value": "38"}]}]}, {"title": "Dermatitis allergic", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}]}]}]}, {"title": "Complications: Breakdown of Malignant Tumors", "description": "Only participants with malignant tumors are reported. Participants may also be counted in more than 1 category.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Gastric cancer", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}, {"title": "Large intestine carcinoma", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}]}]}]}, {"title": "Presence of Medical History", "description": "Breakdown of medical history was categorized as liver disease, renal disease, heart disease, cerebrovascular disease, malignant tumor and any other disease from those mentioned above. Only participants with medical history are presented.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "No", "categories": [{"measurements": [{"groupId": "BG000", "value": "875"}]}]}, {"title": "Yes", "categories": [{"measurements": [{"groupId": "BG000", "value": "143"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "49"}]}]}]}, {"title": "Alcohol History (Drinking Alcohol-Containing Beverages Nearly Every Day)", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "No", "categories": [{"measurements": [{"groupId": "BG000", "value": "597"}]}]}, {"title": "Yes", "categories": [{"measurements": [{"groupId": "BG000", "value": "293"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "177"}]}]}]}, {"title": "Smoking Classification", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Never smoked", "categories": [{"measurements": [{"groupId": "BG000", "value": "499"}]}]}, {"title": "Current smoker", "categories": [{"measurements": [{"groupId": "BG000", "value": "155"}]}]}, {"title": "Ex-smoker", "categories": [{"measurements": [{"groupId": "BG000", "value": "196"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "217"}]}]}]}, {"title": "Status of Administration of Pioglitazone and Metformin Prior to Dosing of Metact Combination Tablets", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Pioglitazone plus metformin prior to dosing", "categories": [{"measurements": [{"groupId": "BG000", "value": "277"}]}]}, {"title": "Pioglitazone alone prior to dosing", "categories": [{"measurements": [{"groupId": "BG000", "value": "442"}]}]}, {"title": "Metformin alone prior to dosing", "categories": [{"measurements": [{"groupId": "BG000", "value": "211"}]}]}, {"title": "Neither pioglitazone nor metformin prior to dosing", "categories": [{"measurements": [{"groupId": "BG000", "value": "137"}]}]}]}, {"title": "Daily Dose of Pioglitazone Prior to Dosing of Metact Combination Tablets", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/day", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "20.5", "spread": "7.60"}]}]}]}, {"title": "Daily Dose of Pioglitazone Prior to Dosing of Metact Combination Tablets", "description": "348 participants did not take pioglitazone prior to dosing of Metact combination tablet.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "\u2264 15 mg/day", "categories": [{"measurements": [{"groupId": "BG000", "value": "456"}]}]}, {"title": "> 15 to \u2264 30 mg/day", "categories": [{"measurements": [{"groupId": "BG000", "value": "258"}]}]}, {"title": "> 30 to \u2264 45 mg/day", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}]}]}, {"title": "> 45 mg/day", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Daily Dose of Pioglitazone Before Switching to Metact Combination Tablets,and Metact Dose Assignment", "description": "Metact LD=1 tablet of Metact Combination Tablets low dose. Metact HD=1 tablet Metact Combination Tablets high dose, Pio=Pioglitazone. 348 participants did not take pioglitazone prior to dosing of Metact combination tablet.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "\u226415 mg/day of Pio to Metact LD", "categories": [{"measurements": [{"groupId": "BG000", "value": "429"}]}]}, {"title": "\u226415 mg/day of Pio to Metact HD", "categories": [{"measurements": [{"groupId": "BG000", "value": "27"}]}]}, {"title": ">15 to \u226430 mg/day of Pio to Metact LD", "categories": [{"measurements": [{"groupId": "BG000", "value": "46"}]}]}, {"title": ">15 to \u226430 mg/day of Pio to Metact HD", "categories": [{"measurements": [{"groupId": "BG000", "value": "212"}]}]}, {"title": ">30 to \u226445 mg/day of Pio to Metact LD", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}, {"title": ">30 to \u226445 mg/day of Pio to Metact HD", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}]}]}, {"title": ">45 mg/day of Pio to Metact LD", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}, {"title": ">45 mg/day of Pio to Metact HD", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Daily Dose of Metformin Prior to Dosing of Metact Combination Tablets", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/day", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "681.4", "spread": "310.08"}]}]}]}, {"title": "Daily Dose of Metformin Prior to Dosing of Metact Combination Tablets", "description": "Participants may be counted in more than 1 category.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< 500 mg/day", "categories": [{"measurements": [{"groupId": "BG000", "value": "25"}]}]}, {"title": "\u2265 500 to < 750 mg/day", "categories": [{"measurements": [{"groupId": "BG000", "value": "229"}]}]}, {"title": "\u2265 750 to < 1500 mg/day", "categories": [{"measurements": [{"groupId": "BG000", "value": "206"}]}]}, {"title": "\u2265 1500 to < 2250 mg/day", "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}]}]}, {"title": "\u2265 2250 mg/day", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}]}]}, {"title": "\u2264 500 mg/day", "categories": [{"measurements": [{"groupId": "BG000", "value": "254"}]}]}, {"title": "> 500 to \u2264 750 mg/day", "categories": [{"measurements": [{"groupId": "BG000", "value": "163"}]}]}, {"title": "> 750 mg/day", "categories": [{"measurements": [{"groupId": "BG000", "value": "71"}]}]}, {"title": "> 500 mg/day", "categories": [{"measurements": [{"groupId": "BG000", "value": "234"}]}]}]}, {"title": "Daily Dose of Metformin Before Switching to Metact Combination Tablets,and Metact Dose Assignment", "description": "Metact LD=1 tablet of Metact Combination Tablets low dose. Metact HD=1 tablet Metact Combination Tablets high dose, Pio=Pioglitazone. Participants could be counted in more than 1 category. 579 participants did not take Metformin prior to dosing of Metact combination tablet.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "<500 mg/day of Met to Metact LD", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}]}]}, {"title": "<500 mg/day of Met to Metact HD", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}]}]}, {"title": "\u2265500 to <750 mg/day of Met to Metact LD", "categories": [{"measurements": [{"groupId": "BG000", "value": "174"}]}]}, {"title": "\u2265500 to <750 mg/day of Met to Metact HD", "categories": [{"measurements": [{"groupId": "BG000", "value": "55"}]}]}, {"title": "\u2265750 to <1500 mg/day of Met to Metact LD", "categories": [{"measurements": [{"groupId": "BG000", "value": "155"}]}]}, {"title": "\u2265750 to <1500 mg/day of Met to Metact HD", "categories": [{"measurements": [{"groupId": "BG000", "value": "49"}]}]}, {"title": "\u22651500 to <2250 mg/day of Met to Metact LD", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}]}]}, {"title": "\u22651500 to <2250 mg/day of Met to Metact HD", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}]}]}, {"title": "\u22652250 mg/day of Met to Metact LD", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}, {"title": "\u22652250 mg/day of Met to Metact HD", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}]}]}, {"title": "\u2264500 mg/day of Met to Metact LD", "categories": [{"measurements": [{"groupId": "BG000", "value": "193"}]}]}, {"title": "\u2264500 mg/day of Met to Metact HD", "categories": [{"measurements": [{"groupId": "BG000", "value": "61"}]}]}, {"title": ">500 to \u2264750 mg/day of Met to Metact LD", "categories": [{"measurements": [{"groupId": "BG000", "value": "124"}]}]}, {"title": ">500 to \u2264750 mg/day of Met to Metact HD", "categories": [{"measurements": [{"groupId": "BG000", "value": "37"}]}]}, {"title": ">750 mg/day of Met to Metact LD", "categories": [{"measurements": [{"groupId": "BG000", "value": "45"}]}]}, {"title": ">750 mg/day of Met to Metact HD", "categories": [{"measurements": [{"groupId": "BG000", "value": "26"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}]}, {"title": "Compliance Status of Pioglitazone (Within 3 Months Before Switching to Metact Combination Tablets)", "description": "348 participants did not take pioglitazone prior to dosing of Metact combination tablet.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "\u2265 90%", "categories": [{"measurements": [{"groupId": "BG000", "value": "534"}]}]}, {"title": "\u2265 70%", "categories": [{"measurements": [{"groupId": "BG000", "value": "142"}]}]}, {"title": "\u2265 50%", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}]}]}, {"title": "< 50%", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}]}]}]}, {"title": "Compliance Status of Metformin (Within 3 Months Before Switching to Metact Combination Tablets)", "description": "579 participants did not take Metformin prior to dosing of Metact combination tablet.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "\u2265 90%", "categories": [{"measurements": [{"groupId": "BG000", "value": "380"}]}]}, {"title": "\u2265 70%", "categories": [{"measurements": [{"groupId": "BG000", "value": "75"}]}]}, {"title": "\u2265 50%", "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}]}]}, {"title": "< 50%", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}]}]}]}, {"title": "Frequency of daily dosing of Metformin prior to dosing of Metact Combination Tablets", "description": "579 participants did not take Metformin prior to dosing of Metact combination tablet. TID = Three times a day.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Daily", "categories": [{"measurements": [{"groupId": "BG000", "value": "58"}]}]}, {"title": "BID", "categories": [{"measurements": [{"groupId": "BG000", "value": "246"}]}]}, {"title": "TID or more", "categories": [{"measurements": [{"groupId": "BG000", "value": "184"}]}]}]}, {"title": "Switch from metformin (> 500 mg/day) to Metact Combination Tablets", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "No", "categories": [{"measurements": [{"groupId": "BG000", "value": "833"}]}]}, {"title": "Yes", "categories": [{"measurements": [{"groupId": "BG000", "value": "234"}]}]}]}, {"title": "Response to pioglitazone in Pioglitazone monotherapy prior to dosing of Metact Combination Tablets", "description": "625 participants did not take pioglitazone in pioglitazone monotherapy prior to dosing of Metact combination tablet.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Inadequate responders", "categories": [{"measurements": [{"groupId": "BG000", "value": "307", "spread": "7.60"}]}]}, {"title": "Patients excluding inadequate responders", "categories": [{"measurements": [{"groupId": "BG000", "value": "74"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "61"}]}]}]}, {"title": "Daily dose in Pioglitazone monotherapy prior to dosing of Metact Combination Tablets", "description": "Participants who responded poorly to pioglitazone treatment were reported. 760 participants did not take pioglitazone in Pioglitazone monotherapy prior to dosing of Metact combination tablet in patients who responded poorly to pioglitazone treatment.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/day", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "20.7", "spread": "7.60"}]}]}]}, {"title": "Daily dose in Pioglitazone monotherapy prior to dosing of Metact Combination Tablets", "description": "Participants who responded poorly to pioglitazone treatment were reported. 760 participants did not take pioglitazone in Pioglitazone monotherapy prior to dosing of Metact combination tablet in patients who responded poorly to pioglitazone treatment.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "\u2264 15 mg/day", "categories": [{"measurements": [{"groupId": "BG000", "value": "191"}]}]}, {"title": "> 15 mg/day to \u2264 30 mg/day", "categories": [{"measurements": [{"groupId": "BG000", "value": "114"}]}]}, {"title": "> 30 mg/day to \u2264 45 mg/day", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}, {"title": "> 45 mg/day", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Daily dose in Pioglitazone monotherapy prior to switching to Metact Combination Tablets", "description": "Participants who responded poorly to pioglitazone treatment were reported. 760 participants did not take pioglitazone in Pioglitazone monotherapy prior to dosing of Metact combination tablet in patients who responded poorly to pioglitazone treatment.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "\u2264 15 mg/day of Pio to Metact LD", "categories": [{"measurements": [{"groupId": "BG000", "value": "178"}]}]}, {"title": "\u2264 15 mg/day of Pio to Metact HD", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}]}]}, {"title": "> 15 mg/day to \u2264 30 mg/day of Pio to Metact LD", "categories": [{"measurements": [{"groupId": "BG000", "value": "21"}]}]}, {"title": "> 15 mg/day to \u2264 30 mg/day of Pio to Metact HD", "categories": [{"measurements": [{"groupId": "BG000", "value": "93"}]}]}, {"title": "> 30 mg/day to \u2264 45 mg/day of Pio to Metact LD", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}, {"title": "> 30 mg/day to \u2264 45 mg/day of Pio to Metact HD", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}, {"title": "> 45 mg/day of Pio to Metact LD", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}, {"title": "> 45 mg/day of Pio to Metact HD", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Rate of compliance with the diet regimen at the start of treatment with Metact Combination Tablets", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "\u2265 90%", "categories": [{"measurements": [{"groupId": "BG000", "value": "270"}]}]}, {"title": "\u2265 70%", "categories": [{"measurements": [{"groupId": "BG000", "value": "367"}]}]}, {"title": "\u2265 50%", "categories": [{"measurements": [{"groupId": "BG000", "value": "259"}]}]}, {"title": "< 50%", "categories": [{"measurements": [{"groupId": "BG000", "value": "76"}]}]}, {"title": "Not assessed or compliance status is unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "95"}]}]}]}, {"title": "Rate of compliance with exercise regimen at the start of treatment with Metact Combination Tablets", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "\u2265 90%", "categories": [{"measurements": [{"groupId": "BG000", "value": "205"}]}]}, {"title": "\u2265 70%", "categories": [{"measurements": [{"groupId": "BG000", "value": "294"}]}]}, {"title": "\u2265 50%", "categories": [{"measurements": [{"groupId": "BG000", "value": "305"}]}]}, {"title": "< 50%", "categories": [{"measurements": [{"groupId": "BG000", "value": "135"}]}]}, {"title": "Not assessed or compliance status is unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "128"}]}]}]}, {"title": "HbA1c (NGSP value) at the start of treatment with Metact Combination Tablets", "description": "HbA1c = glycosylated hemoglobin NGSP = National Glycohemoglobin Standardization Program", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of HbA1c", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.69", "spread": "1.369"}]}]}]}, {"title": "Participants with HbA1c (NGSP value) at the start of treatment with Metact Combination Tablets", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< 6.0%", "categories": [{"measurements": [{"groupId": "BG000", "value": "39"}]}]}, {"title": "\u2265 6.0% to < 7.0%", "categories": [{"measurements": [{"groupId": "BG000", "value": "270"}]}]}, {"title": "\u2265 7.0% to < 8.0%", "categories": [{"measurements": [{"groupId": "BG000", "value": "340"}]}]}, {"title": "\u2265 8.0%", "categories": [{"measurements": [{"groupId": "BG000", "value": "290"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "128"}]}]}]}, {"title": "Fasting blood glucose at the start of treatment with Metact Combination Tablets", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "150.1", "spread": "56.43"}]}]}]}, {"title": "Participants with Fasting blood glucose at the start of treatment with Metact Combination Tablets", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< 126 mg/dL", "categories": [{"measurements": [{"groupId": "BG000", "value": "157"}]}]}, {"title": "\u2265 126 to < 140 mg/dL", "categories": [{"measurements": [{"groupId": "BG000", "value": "75"}]}]}, {"title": "\u2265 140 to < 160 mg/dL", "categories": [{"measurements": [{"groupId": "BG000", "value": "80"}]}]}, {"title": "\u2265 160 mg/dL", "categories": [{"measurements": [{"groupId": "BG000", "value": "134"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "621"}]}]}]}, {"title": "Fasting insulin at the start of treatment with Metact Combination Tablets", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "\u03bcU/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "10.775", "spread": "9.0804"}]}]}]}, {"title": "Participants with Fasting insulin at the start of treatment with Metact Combination Tablets", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< 1.0 \u03bcU/dL", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}, {"title": "\u2265 1.0 \u03bcU/dL to < 5.0 \u03bcU/dL", "categories": [{"measurements": [{"groupId": "BG000", "value": "24"}]}]}, {"title": "\u2265 5.0 \u03bcU/dL to < 10.0 \u03bcU/dL", "categories": [{"measurements": [{"groupId": "BG000", "value": "25"}]}]}, {"title": "\u2265 10.0 \u03bcU/dL to < 50.0 \u03bcU/dL", "categories": [{"measurements": [{"groupId": "BG000", "value": "46"}]}]}, {"title": "\u2265 50.0 \u03bcU/dL to < 100.0 \u03bcU/dL", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}, {"title": "\u2265 100 \u03bcU/dL", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "971"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Adverse Drug Reactions", "description": "Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug. Among these, events which are considered possibly associated with a medicinal product are defined as adverse drug reactions.", "populationDescription": "Safety Analysis Set, all patients for whom data was collected in case report forms, except those who were treated before the contract period, those who were enrolled after Day 15 of the start of treatment with Metact Combination Tablets, and those with missing data after treatment (missed visits).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Pioglitazone/Metformin Hydrochloride", "description": "Pioglitazone/metformin hydrochloride combination tablets, orally, for 12 months as prescribed by the standard of care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1067"}]}], "classes": [{"title": "Thyroid cancer", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Anaemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Insomnia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Dizziness", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Dysgeusia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Right ventricular failure", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Dyspnoea exertional", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Abdominal distension", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Constipation", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Nausea", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Hepatic function abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Cold sweat", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Myalgia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Renal impairment", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Chest discomfort", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Face oedema", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Malaise", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Oedema", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}]}]}, {"title": "Oedema peripheral", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}]}]}, {"title": "Cardiothoracic ratio increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Blood cholesterol increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Blood triglycerides increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Lipids abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Blood creatinine increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Weight increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}]}]}, {"title": "Heat illness", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (HbA1c)", "description": "Tabulation of the HbA1c test value and change at each test time point (test value at each test time point after baseline - test value at baseline). A negative change from Baseline indicates improvement. n=number of participants analyzed at each time point. Final assessment is defined as a cumulative assessment of Month 12 and Early Termination Visit data.", "populationDescription": "The analysis was performed in the efficacy assessment population (n=905).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of HbA1c", "timeFrame": "Baseline and Months 3, 6, 9, 12 and final assessment", "groups": [{"id": "OG000", "title": "Pioglitazone/Metformin Hydrochloride", "description": "Pioglitazone/metformin hydrochloride combination tablets, orally, for 12 months as prescribed by the standard of care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "905"}]}], "classes": [{"title": "Month 3 (n=819)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.47", "spread": "1.030"}]}]}, {"title": "Month 6 (n=761)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.53", "spread": "1.142"}]}]}, {"title": "Month 9 (n=681)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.55", "spread": "1.183"}]}]}, {"title": "Month 12 (n=670)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.60", "spread": "1.190"}]}]}, {"title": "Final Assessment (n=896)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.58", "spread": "1.182"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Blood Glucose", "description": "Tabulation of fasting blood glucose test values and change at each test time point (test value at each test time point after baseline - test value at baseline). A negative change from Baseline indicates improvement. n=number of participants analyzed at each time point. Final assessment is defined as a cumulative assessment of Month 12 and Early Termination Visit data.", "populationDescription": "The analysis was performed in the efficacy assessment population (n=905).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Months 3, 6, 9, 12 and final assessment", "groups": [{"id": "OG000", "title": "Pioglitazone/Metformin Hydrochloride", "description": "Pioglitazone/metformin hydrochloride combination tablets, orally, for 12 months as prescribed by the standard of care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "905"}]}], "classes": [{"title": "Month 3 (n=311)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.0", "spread": "41.98"}]}]}, {"title": "Month 6 (n=275)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-15.5", "spread": "40.82"}]}]}, {"title": "Month 9 (n=29)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.7", "spread": "43.16"}]}]}, {"title": "Month 12 (n=255)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-17.3", "spread": "42.97"}]}]}, {"title": "Final Assessment (n=375)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-17.9", "spread": "45.36"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Insulin", "description": "Tabulation of fasting insulin test values and change at each test time point (test value at each test time point after baseline - test value at baseline). A negative change from Baseline indicates improvement. n=number of participants analyzed at each time point. Final assessment is defined as a cumulative assessment of Month 12 and Early Termination Visit data.", "populationDescription": "The analysis was performed in the efficacy assessment population (n=905).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u03bcU/dL", "timeFrame": "Baseline and Months 3, 6, 9, 12 and final assessment", "groups": [{"id": "OG000", "title": "Pioglitazone/Metformin Hydrochloride", "description": "Pioglitazone/metformin hydrochloride combination tablets, orally, for 12 months as prescribed by the standard of care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "905"}]}], "classes": [{"title": "Month 3 (n=22)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.768", "spread": "4.2928"}]}]}, {"title": "Month 6 (n=46)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.374", "spread": "7.0954"}]}]}, {"title": "Month 9 (n=22)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.018", "spread": "5.9072"}]}]}, {"title": "Month 12 (n=51)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.524", "spread": "9.4260"}]}]}, {"title": "Final Assessment (n=63)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.107", "spread": "8.7360"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From baseline to 12 months of treatment.", "description": "At each visit the investigator documented occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by participant or observed by investigator was recorded, irrespective of relation to study treatment. The same PTs (Preferred Term) coded for same patient with differing LLTs (Low Level Terms) are counted twice.", "eventGroups": [{"id": "EG000", "title": "Pioglitazone/Metformin Hydrochloride", "description": "Pioglitazone/metformin hydrochloride combination tablets, orally, for 12 months as prescribed by the standard of care.", "seriousNumAffected": 18, "seriousNumAtRisk": 1067, "otherNumAffected": 0, "otherNumAtRisk": 1067}], "seriousEvents": [{"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1067}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Gastric cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Malignant ascites", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Rectal cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Uterine cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Thyroid cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 1067}]}, {"term": "Diabetic hyperglycaemic coma", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Interstitial lung disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Liver disorder", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Sudden death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Femur fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Radius fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Ulna fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}, {"term": "Heat illness", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1067}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property."}, "pointOfContact": {"title": "Medical Director, Clinical Science", "organization": "Takeda Pharmaceuticals Company Limited", "email": "trialdisclosures@takeda.com", "phone": "+1-877-825-3327"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000077205", "term": "Pioglitazone"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Facial", "relevance": "HIGH"}, {"id": "M1693", "name": "Pioglitazone", "asFound": "Registry", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}